Mode
Text Size
Log in / Sign up

Current narrative review examines sepsis-associated encephalopathy mechanisms and therapeutic implications.

Current narrative review examines sepsis-associated encephalopathy mechanisms and therapeutic implic…
Photo by charlesdeluvio / Unsplash
Key Takeaway
Recognize that inflammatory modulation therapies for sepsis-associated encephalopathy lack established protocols and mechanistic clarity.

This publication is a narrative review addressing the complex pathophysiology of sepsis-associated encephalopathy. Unlike primary trials, this source does not report specific study populations, sample sizes, or intervention comparators. Instead, it synthesizes existing knowledge regarding the neurological complications arising from systemic infection. The scope centers on the role of microglia within the central nervous system during septic events.

The authors discuss the transition from a systemic response to a pathological state within the brain. Key arguments highlight the potential for inflammatory modulation therapies to reverse the pathological state of microglia. The text suggests restoring the protective surveillance role of these cells could be beneficial. However, the main results section is empty, indicating a lack of pooled effect sizes or quantitative data typical of meta-analyses.

Significant limitations are acknowledged by the authors regarding current mechanistic understanding. Specifically, the exact mechanism by which microglial phenotype change is mediated remains to be understood. Furthermore, the mechanism by which a pathological state develops from a systemic response remains to be understood. These gaps highlight the preliminary nature of the current evidence base.

Practice relevance is framed around future therapeutic development rather than immediate clinical application. The review provides a basis for developing novel inflammatory modulation therapies. Clinicians should recognize that while the biological rationale is presented, specific treatment protocols are not established. The evidence remains theoretical pending further investigation into the identified mechanistic gaps.

Safety data is not reported within this narrative summary. No adverse events, serious adverse events, or discontinuations are documented. Consequently, risk profiles for any discussed interventions are unknown. This absence of safety reporting reinforces the need for caution when interpreting the therapeutic implications presented in the text.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Microglia, being the resident immunological sentinels of the central nervous system (CNS), play a critical role in both the pathogenesis and progression of CNS health and disease. In sepsis-associated encephalopathy (SAE), it is increasingly evident that the phenotype and function of microglia may change from a neuroprotective phenotype to a potential effector phenotype with neurotoxic potential. However, the exact mechanism by which this change is mediated remains to be understood. The current body of research is mostly focused on the hyperactivation of microglia, while the mechanism by which a pathological state develops from a systemic response remains to be understood. This limits the ability to design precise therapeutic strategies to target this cell population. In this regard, a framework of pathological state reprogramming is proposed to systematically evaluate potential mechanisms of microglial dysfunction in SAE. In this review, we will attempt to integrate the body of knowledge from single cell multi-omics, functional genetics, and in vivo imaging to determine the molecular characteristics of SAE-associated microglial states and potential functional alterations such as synaptic pruning. Further discuss the key factors that contribute to this evolution, such as inflammatory signaling, transcriptional and epigenetic regulation networks, and metabolic remodeling; and based on this basis, discuss multi-level therapeutic strategies for reversing the pathological state and restoring their protective role. These include potential strategies such as epigenetic and metabolic pathway modulation, CRISPR-mediated gene regulation, and cell therapies. These strategies consider microglia as a functional entity that has plasticity and can be modulated. The mechanistic basis developed in this review not only helps in understanding the pathology of SAE but also provides a basis for developing novel inflammatory modulation therapies for reversing the pathological state of microglia and restoring their protective surveillance role. This mechanistic basis for therapeutic innovation has a wide range of implications for developing intervention strategies for neuroinflammatory disorders.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.